Placebo response in depression: Bane of research, boon to therapy

British Journal of Psychiatry

Volumn 178, Issue MARCH., 2001, Pages 192-194

  Andrews, G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEW DRUG; PLACEBO;

ANXIETY NEUROSIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RESEARCH; EDITORIAL; HUMAN; META ANALYSIS; REMISSION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS; REMISSION, SPONTANEOUS;

EID: 0035118638     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.178.3.192     Document Type: Editorial

References (26)

1. The essential psychotherapies
2. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment
3. Can the placebo be the cure?
4. Antidepressant treatment of depression: A meta-analysis
5. Public knowledge of and attitudes to mental disorders: A limiting factor in the optimal use of treatment services
6. The prediction of length of major depressive episodes: Results from an epidemiological survey of female twins
7. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials
8. Listening to prozac but hearing placebo: A meta-analysis of antidepressant medication
9. Statistical analysis to settle ethical issues?
10. Speed of recovery from major depressive episodes in a community sample of married men and women
11. Metaanalysis of trials comparing antidepressants with active placebos
12. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care
13. A treatment outline for agoraphobia
14. A treatment outline for depressive disorders
15. A treatment outline for the management of schizophrenia
16. Treatment outlines for the management of anxiety states
17. Treatment outlines for the management of obsessive-compulsive disorders
18. Validity of clinical trials of antidepressants
19. How should efficacy be evaluated in randomized clinical trials of treatments for depression?